We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Pharmaceutical Executive Joins Mesoblast as Chief Financial Officer
News

Pharmaceutical Executive Joins Mesoblast as Chief Financial Officer

Pharmaceutical Executive Joins Mesoblast as Chief Financial Officer
News

Pharmaceutical Executive Joins Mesoblast as Chief Financial Officer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Pharmaceutical Executive Joins Mesoblast as Chief Financial Officer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Mesoblast Limited has announced the appointment of pharmaceutical executive Mr Paul Hodgkinson as Mesoblast Chief Financial Officer.

Mr Hodgkinson has broad and high-level international pharmaceutical experience in all aspects of finance, strategic planning, business development and licensing, manufacturing and supply chain, and procurement.

From 2011 to 2014, Mr Hodgkinson was Chief Financial Officer and had full financial responsibility for the Novartis ANZ Group of companies and divisions comprising Pharmaceuticals, Alcon, Sandoz, Vaccines and Diagnostics, Consumer and Animal Health.

Previously, he held a number of leadership roles with AstraZeneca in the United Kingdom, including Global Licensing Finance Director, before being appointed Chief Financial Officer for AstraZeneca Australia from 2006 to 2011.

After seven years in Mesoblast’s executive team as Chief Financial Officer and Company Secretary, Ms Jenni Pilcher will depart on 31 August to take up a new role with an Australian biotechnology company as Chief Financial Officer.

The Mesoblast Board and management thank Ms Pilcher for her important contribution to the growth of the company and wish her well in her new position.

Advertisement